AZD4017   Click here for help

GtoPdb Ligand ID: 7695

Synonyms: AZD 4017 | AZD-4017
PDB Ligand
Compound class: Synthetic organic
Comment: AZD4017 is a selective inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) [2-3]. This compound is listed in AstraZeneca's OpenInnovation Pharmacology Toolbox .
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 9
Topological polar surface area 107.83
Molecular weight 419.22
XLogP 4.88
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCCSc1nc(ccc1C(=O)NC1CCCCC1)N1CCCC(C1)CC(=O)O
Isomeric SMILES CCCSc1nc(ccc1C(=O)NC1CCCCC1)N1CCC[C@H](C1)CC(=O)O
InChI InChI=1S/C22H33N3O3S/c1-2-13-29-22-18(21(28)23-17-8-4-3-5-9-17)10-11-19(24-22)25-12-6-7-16(15-25)14-20(26)27/h10-11,16-17H,2-9,12-15H2,1H3,(H,23,28)(H,26,27)/t16-/m0/s1
InChI Key NCDZABJPWMBMIQ-INIZCTEOSA-N
References
1. Eckel RH, Grundy SM, Zimmet PZ. (2005)
The metabolic syndrome.
Lancet, 365 (9468): 1415-28. [PMID:15836891]
2. McCoull W, Packer M, Scott JS , Whittamore PRO. (2009)
Chemical compounds.
Patent number: US20090306075. Assignee: Astrazeneca Ab. Priority date: 03/11/2006. Publication date: 10/12/2009.
3. Scott JS, Bowker SS, Deschoolmeester J, Gerhardt S, Hargreaves D, Kilgour E, Lloyd A, Mayers RM, McCoull W, Newcombe NJ et al.. (2012)
Discovery of a potent, selective, and orally bioavailable acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor: discovery of 2-[(3S)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-3-piperidyl]acetic acid (AZD4017).
J Med Chem, 55 (12): 5951-64. [PMID:22691057]
4. Stimson RH, Walker BR. (2007)
Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
Minerva Endocrinol, 32 (3): 141-59. [PMID:17912154]
5. Walker BR. (2007)
Glucocorticoids and cardiovascular disease.
Eur J Endocrinol, 157 (5): 545-59. [PMID:17984234]